UFP 803Urotensin-II (UT) antagonist CAS# 879497-82-2 |
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 879497-82-2 | SDF | Download SDF |
| PubChem ID | 56972202 | Appearance | Powder |
| Formula | C50H64N10O12S2 | M.Wt | 1061.24 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in sterile water | ||
| Sequence | DXFWXYCV (Modifications: X-2 = Pen, Trp-4 = D-Trp, X-5 = Dab, Disulfide bridge between 2 - 7) | ||
| Chemical Name | (2S)-2-[[(4R,7S,10S,13R,16S,19R)-19-[[(2S)-2-amino-3-carboxypropanoyl]amino]-10-(2-aminoethyl)-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoic acid | ||
| SMILES | CC(C)C(C(=O)O)NC(=O)C1CSSC(C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)CCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)NC(=O)C(CC(=O)O)N)(C)C | ||
| Standard InChIKey | LRELVPJTCGYTSS-XKDXTNGGSA-N | ||
| Standard InChI | InChI=1S/C50H64N10O12S2/c1-26(2)40(49(71)72)59-47(69)38-25-73-74-50(3,4)41(60-42(64)32(52)23-39(62)63)48(70)57-36(20-27-10-6-5-7-11-27)44(66)56-37(22-29-24-53-33-13-9-8-12-31(29)33)46(68)54-34(18-19-51)43(65)55-35(45(67)58-38)21-28-14-16-30(61)17-15-28/h5-17,24,26,32,34-38,40-41,53,61H,18-23,25,51-52H2,1-4H3,(H,54,68)(H,55,65)(H,56,66)(H,57,70)(H,58,67)(H,59,69)(H,60,64)(H,62,63)(H,71,72)/t32-,34-,35-,36-,37+,38-,40-,41+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Urotensin-II (UT) receptor ligand; behaves as a silent antagonist in most in vitro assays and in vivo, but does retain small residual agonist activity under certain conditions in some assays. Competitively antagonizes U-II induced contractions in the rat aorta (pIC50 = 7.46) and prevents plasma extravasation elicited by U-II in mice in vivo. |
UFP 803 Dilution Calculator
UFP 803 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Prionoid E
Catalog No.:BCN3161
CAS No.:879324-78-4
- Prionoid D
Catalog No.:BCN3160
CAS No.:879324-77-3
- Prionoid C
Catalog No.:BCN3159
CAS No.:879324-76-2
- Prionoid B
Catalog No.:BCN3217
CAS No.:879324-75-1
- p-Hydroxyphenethyl anisate
Catalog No.:BCN6896
CAS No.:87932-34-1
- 3,4,5-Tri-O-galloylquinic acid
Catalog No.:BCN8027
CAS No.:99745-62-7
- Psoracorylifol C
Catalog No.:BCN3708
CAS No.:879290-99-0
- Psoracorylifol B
Catalog No.:BCN7884
CAS No.:879290-98-9
- Psoracorylifol A
Catalog No.:BCN3611
CAS No.:879290-97-8
- CP 93129 dihydrochloride
Catalog No.:BCC6899
CAS No.:879089-64-2
- GDC-0449 (Vismodegib)
Catalog No.:BCC1285
CAS No.:879085-55-9
- 15-deoxy-Δ-12,14-Prostaglandin J2
Catalog No.:BCC7321
CAS No.:87893-55-8
- Ingenol-5,20-acetonide-3-O-angelate
Catalog No.:BCN8458
CAS No.:87980-68-5
- Furan-2-carboxylic acid
Catalog No.:BCN4557
CAS No.:88-14-2
- 2-Acetylthiophene
Catalog No.:BCC8517
CAS No.:88-15-3
- BHQ
Catalog No.:BCC6982
CAS No.:88-58-4
- 1,2-Benzenedicarboxylic acid
Catalog No.:BCN3151
CAS No.:88-99-3
- Neuropathiazol
Catalog No.:BCC5375
CAS No.:880090-88-0
- Fmoc-Hyp-OH
Catalog No.:BCC3254
CAS No.:88050-17-3
- AMD-070 hydrochloride
Catalog No.:BCC1358
CAS No.:880549-30-4
- Naloxonazine dihydrochloride
Catalog No.:BCC6710
CAS No.:880759-65-9
- PhiKan 083
Catalog No.:BCC2411
CAS No.:880813-36-5
- 4-Hydroxybenzaldehyde rhamnoside
Catalog No.:BCN7625
CAS No.:88086-86-6
- Phrixotoxin 3
Catalog No.:BCC6328
CAS No.:880886-00-0
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).[Pubmed:16273120]
Br J Pharmacol. 2006 Jan;147(1):92-100.
The novel urotensin-II (U-II) receptor (UT) ligand, [Pen(5),DTrp(7),Dab(8)]U-II(4-11) (UFP-803), was pharmacologically evaluated and compared with urantide in in vitro and in vivo assays. In the rat isolated aorta, UFP-803 was inactive alone but, concentration dependently, displaced the contractile response to U-II to the right, revealing a competitive type of antagonism and a pA(2) value of 7.46. In the FLIPR [Ca(2+)](i) assay, performed at room temperature in HEK293(hUT) and HEK293(rUT) cells, U-II increased [Ca(2+)](i) with pEC(50) values of 8.11 and 8.48. Urantide and UFP-803 were inactive as agonists, but antagonized the actions of U-II by reducing, in a concentration-dependent manner, the agonist maximal effects with apparent pK(B) values in the range of 8.45-9.05. In a separate series of experiments performed at 37 degrees C using a cuvette-based [Ca(2+)](i) assay and CHO(hUT) cells, urantide mimicked the [Ca(2+)](i) stimulatory effect of U-II with an intrinsic activity (alpha) of 0.80, while UFP-803 displayed a small (alpha=0.21) but consistent residual agonist activity. When the same experiments were repeated at 22 degrees C (a temperature similar to that in FLIPR experiments), urantide displayed a very small intrinsic activity (alpha=0.11) and UFP-803 was completely inactive as an agonist. In vivo in mice, UFP-803 (10 nmol kg(-1)) antagonized U-II (1 nmol kg(-1))-induced increase in plasma extravasation in various vascular beds, while being inactive alone. In conclusion, UFP-803 is a potent UT receptor ligand which displays competitive/noncompetitive antagonist behavior depending on the assay. While UFP-803 is less potent than urantide, it displayed reduced residual agonist activity and as such may be a useful pharmacological tool.
